Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$27.97 +1.3%	$20.96	$16.10 ▼ $41.94	$3.53B	0.78	3.15 million shs	1.82 million shs
CXRXF ADVANZ PHARMA	$17.06	$17.06	$2.13 ▼ $18.00	$834.46M	N/A	11,851 shs	39 shs
MTSR Metsera	$33.05 +0.8%	$33.31	$12.30 ▼ $47.40	$3.47B	N/A	1.53 million shs	1.24 million shs
PTGX Protagonist Therapeutics	$57.48 +2.6%	$54.15	$33.31 ▼ $60.60	$3.58B	2.33	605,768 shs	470,129 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	0.00%	+0.79%	+39.22%	+60.38%	-29.82%
CXRXF ADVANZ PHARMA	0.00%	0.00%	0.00%	0.00%	0.00%
MTSR Metsera	0.00%	+6.13%	-16.65%	+21.06%	+3,304,999,900.00%
PTGX Protagonist Therapeutics	0.00%	+2.51%	+6.96%	+25.89%	+38.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.1708 of 5 stars	3.3	1.0	0.0	4.4	3.5	2.5	0.6
CXRXF ADVANZ PHARMA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	1.7984 of 5 stars	2.5	3.0	0.0	0.0	2.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.58	Moderate Buy	$34.12	21.98% Upside
CXRXF ADVANZ PHARMA	0.00	N/A	N/A	N/A
MTSR Metsera	3.00	Buy	$55.00	66.41% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$67.20	16.91% Upside

Current Analyst Ratings Breakdown

Latest CXRXF, MTSR, PTGX, and APLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	PTGX Protagonist Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$67.00 ➝ $69.00
8/4/2025	APLS Apellis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$35.00 ➝ $37.00
8/1/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$17.00 ➝ $19.00
8/1/2025	APLS Apellis Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$39.00 ➝ $40.00
8/1/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$52.00 ➝ $50.00
7/29/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$41.00 ➝ $46.00
7/18/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$47.00 ➝ $50.00
7/16/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
7/2/2025	APLS Apellis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $26.00
6/20/2025	MTSR Metsera	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	4.52	N/A	N/A	$1.24 per share	22.56
CXRXF ADVANZ PHARMA	$525.58M	1.59	N/A	N/A	$0.16 per share	106.63
MTSR Metsera	N/A	N/A	N/A	N/A	$4.28 per share	N/A
PTGX Protagonist Therapeutics	$434.43M	8.23	$4.52 per share	12.72	$10.74 per share	5.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	11/4/2025 (Estimated)
CXRXF ADVANZ PHARMA	-$74.86M	N/A	N/A	∞	N/A	-15.31%	N/A	-4.38%	N/A
MTSR Metsera	-$209.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	$275.19M	$0.70	82.12	N/A	N/A	24.88%	8.12%	7.41%	11/6/2025 (Estimated)

Latest CXRXF, MTSR, PTGX, and APLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	-$0.55	-$0.02	-$0.55	$8.32 million	$5.55 million
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million
7/28/2025	Q2 2025	MTSR Metsera	N/A	-$0.66	N/A	-$0.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CXRXF ADVANZ PHARMA	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
CXRXF ADVANZ PHARMA	257.04	2.39	1.61
MTSR Metsera	N/A	5.26	5.26
PTGX Protagonist Therapeutics	N/A	16.97	16.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
CXRXF ADVANZ PHARMA	N/A
MTSR Metsera	N/A
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
CXRXF ADVANZ PHARMA	N/A
MTSR Metsera	N/A
PTGX Protagonist Therapeutics	4.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	118.08 million	Optionable
CXRXF ADVANZ PHARMA	429	48.91 million	N/A	Not Optionable
MTSR Metsera	81	105.06 million	N/A	N/A
PTGX Protagonist Therapeutics	120	62.21 million	59.16 million	Optionable

CXRXF, MTSR, PTGX, and APLS Headlines

Recent News About These Companies

State of New Jersey Common Pension Fund D Purchases Shares of 53,736 Protagonist Therapeutics, Inc. $PTGX

2 hours ago | marketbeat.com

Protagonist Therapeutics, Inc. $PTGX Shares Sold by American Century Companies Inc.

3 hours ago | marketbeat.com

Charles Schwab Investment Management Inc. Sells 20,691 Shares of Protagonist Therapeutics, Inc. $PTGX

August 23 at 3:35 AM | marketbeat.com

Vanguard Group Inc. Has $206.85 Million Holdings in Protagonist Therapeutics, Inc. $PTGX

August 22 at 3:18 AM | marketbeat.com

Invesco Ltd. Has $41.57 Million Position in Protagonist Therapeutics, Inc. $PTGX

August 20, 2025 | marketbeat.com

Deutsche Bank AG Has $3.18 Million Holdings in Protagonist Therapeutics, Inc. $PTGX

August 20, 2025 | marketbeat.com

E Fund Management Co. Ltd. Sells 71,950 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 18, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Public Sector Pension Investment Board

August 15, 2025 | marketbeat.com

Informed Momentum Co LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 13, 2025 | marketbeat.com

Knott David M Jr Purchases 23,632 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 12, 2025 | marketbeat.com

Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot?

August 12, 2025 | finance.yahoo.com

Wedbush Has Positive Estimate for PTGX Q3 Earnings

August 11, 2025 | marketbeat.com

Wedbush Expects Higher Earnings for Protagonist Therapeutics

August 9, 2025 | marketbeat.com

7PTGX : What 4 Analyst Ratings Have To Say About Protagonist...

August 8, 2025 | benzinga.com

JMP Securities Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock

August 8, 2025 | marketbeat.com

Protagonist Therapeutics files automatic mixed securities shelf

August 7, 2025 | msn.com

Protagonist (PTGX) Q2 Revenue Falls 26%

August 7, 2025 | fool.com

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 6, 2025 | accessnewswire.comA

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Raised by XTX Topco Ltd

August 5, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by Analysts

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CXRXF, MTSR, PTGX, and APLS Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$27.97 +0.35 (+1.27%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$27.92 -0.04 (-0.16%)

As of 08/22/2025 06:44 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

ADVANZ PHARMA OTCMKTS:CXRXF

$17.06 0.00 (0.00%)

As of 06/10/2021

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

Metsera NASDAQ:MTSR

$33.05 +0.25 (+0.76%)

As of 08/22/2025 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Protagonist Therapeutics NASDAQ:PTGX

$57.48 +1.44 (+2.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$57.48 +0.01 (+0.01%)

As of 08/22/2025 06:02 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time